Articles Vol. 67 No. 6 25/06/2026

ASSOCIATION BETWEEN CLINICAL AND LABORATORY FINDINGS AND TYROSINE KINASE TREATMENT RESPONSE IN EGFR-MUTATED NON-SMALL CELL LUNG CANCER PATIENTS AT 19-8 HOSPITAL

Nguyen Thi Minh Hai1,2, Nguyen Hai Dang3,4, Hoang Thi Ngoc Tram5,6
1 19-8 Hospital
2 Bệnh viện 19-8
3 Faculty of Medicine and Pharmacy, Academy of Security Engineering and Technology
4 Khoa Y Dược, Học viện Kỹ thuật và Công nghệ an ninh
5 University of Medicine and Pharmacy, Thai Nguyen University
6 Trường Đại học Y Dược, Đại học Thái Nguyên
DOI: 10.52163/yhc.v67i6.5490
22 Views
13 Downloads
Keywords
TKI, EGFR gene mutation, non-small cell lung cancer, exon 19, exon 21.
Abstract

Objectives: To describe the clinical and paraclinical characteristics and to evaluate the association of these features with the response to Tyrosine Kinase Inhibitors (TKI) in non-small cell lung cancer patients with EGFR gene mutation at 19-8 Hospital.

Patients and methods: A clinical intervention, cross-sectional descriptive study, combining retrospective and prospective analysis without a control group, was conducted on 30 patients with stage IV EGFR-mutant non-small cell lung cancer receiving first-line TKI therapy from January 2022 to November 2024.

Results: The mean age was 62.2 ± 13.3 years; the male-to-female ratio was 2:1. Patients with an ECOG performance status of 0-1 accounted for the vast majority (96.6%), with no recorded cases of ECOG = 3. Single-site/organ metastasis was the most common presentation (46.7%), while EGFR gene mutation on exon 19 were more frequent (63.3%). Although no statistically significant difference was found between treatment response rates and clinical, paraclinical factors, or TKI types (p > 0.05), Osimertinib showed the best response (100%), and exon 19 mutations responded better than exon 21 mutations (84.2% vs. 54.5%).

Conclusion: The study found no statistically significant correlation between clinical or paraclinical factors and TKI treatment response in patients with stage IV EGFR-mutant non-small cell lung cancer.

References
[1]
Bray F et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2024, 74 (3): 229-63. doi: 10.3322/caac.21834 Google Scholar
[2]
Hsu W.H et al. Overview of current systemic management of EGFR-mutant NSCLC. Ann Oncol, 2018, 29 (suppl_1): i3-i9. doi: 10.1093/annonc/mdx702 Google Scholar
[3]
Shi Y et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol, 2014, 9 (2): 154-62. doi: 10.1097/JTO.0000000000000033 Google Scholar
[4]
Majeed U et al. Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. J Hematol Oncol, 2021, 14 (1):108. doi: 10.1186/s13045-021-01121-2 Google Scholar
[5]
Phạm Văn Luận và cộng sự. So sánh hiệu quả điều trị bước một của Afatinib và Gefitinib ở bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn tiến xa có đột biến gen EGFR thường gặp. Tạp chí Y Dược lâm sàng 108, 2024, 19 (5): 55-63. doi: 10.52389/ydls.v19i5.2265 Google Scholar
[6]
Zhou C et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011, 12 (8): 735-42. doi: 10.1016/S1470-2045(11)70184-X Google Scholar
[7]
Rosell R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 2012, 13 (3): 239-46. doi: 10.1016/S1470-2045(11)70393-X Google Scholar
[8]
Soria J.C et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med, 2018, 378 (2): 113-25. doi: 10.1056/NEJMoa1713137 Google Scholar
[9]
Nghiêm Trần Vượng. Đánh giá kết quả Erlotinib trong điều trị bước một ung thư phổi không tế bào nhỏ giai đoạn IV có đột biến EGFR. Luận văn tốt nghiệp bác sĩ nội trú, Trường Đại học Y Hà Nội, 2020. Google Scholar
[10]
Paz-Ares L et al. Afatinib versus Gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann Oncol, 2017, 28 (2): 270-7. doi: 10.1093/annonc/mdw611. Google Scholar